References
- James C, Ugo V, Le Couedic JP, et al A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005. 434:1144–1148.
- Kralovics R, Passamonti F, Buser AS, et al A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005. 352:1779–1790.
- Levine RL, Wadleigh M, Cools J, et al Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005. 7:387–397.
- Baxter EJ, Scott LM, Campbell PJ, et al Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005. 365:1054–1061.
- Pardanani AD, Levine RL, Lasho T, et al MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006. 108:3472–3476.
- Ma W, Kantarjian H, Zhang X, et al Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009. 11:49–53.
- Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008. 22:14–22.
- Kalnina Z, Zayakin P, Silina K, et al Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer. 2005. 42:342–357.
- Laudadio J, Deininger MW, Mauro MJ, et al An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients under going kinase inhibitor therapy. J Mol Diagn. 2008. 10:177–180.